CYTOF.US Altamira Therapeutics Ltd.

Healthcare Biotechnology USA Stocks
0.0710 USD
Close of Nov 14, 2026
0.0500 0.1470
Market cap
USD 406K
P/E
-
P/B
0.10x
ROE
-128.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is CYTOF.US undervalued?

Graham number

The Graham number of Altamira Therapeutics Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Altamira Therapeutics Ltd. fundamental analysis

No fundamental analysis for Altamira Therapeutics Ltd. yet.

Altamira Therapeutics Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the tre…

Full company profile